Tags

Type your tag names separated by a space and hit enter

Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights.

Abstract

The polycystic ovary syndrome (PCOS) affects 5-10% of all premenopausal women. It is diagnosed by a combination of oligo-amenorrhea and hyperandrogenism (NIH criteria) or by the presence of two out of three of: oligo-amenorrhea, hyperandrogenism, polycystic ovaries on ultrasound (Rotterdam criteria). PCOS is associated with obesity, insulin resistance and dyslipidemia. Different patterns of dyslipidemia can be present, both in lean and obese PCOS. Low HDL-cholesterol, with or without elevated TG, is the most prominent lipid abnormality. In addition, smaller HDL and LDL particles and elevated postprandial TG responses are reported. Hyperandrogenism, anovulation and insulin resistance affect multiple steps in lipid metabolism in PCOS, as will be discussed. Surrogate markers for atherosclerosis are consistently abnormal in PCOS, while studies on clinical CVD endpoints are limited and non-conclusive. The (pharmaco-) therapy of dyslipidemia in PCOS will be discussed. In addition, the effects of other PCOS related (pharmaco-) therapies, primarily aimed at hyperandrogenism, anovulation or insulin resistance, on lipid metabolism will be addressed.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Internal Medicine, University Medical Center Utrecht, The Netherlands. h.e.westerveld@umcutrecht.nl

    , , , ,

    Source

    Pharmacology & therapeutics 119:3 2008 Sep pg 223-41

    MeSH

    Anovulation
    Dyslipidemias
    Female
    Humans
    Hyperandrogenism
    Models, Biological
    Polycystic Ovary Syndrome

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    18602948

    Citation

    Westerveld, H E., et al. "Cardiometabolic Abnormalities in the Polycystic Ovary Syndrome: Pharmacotherapeutic Insights." Pharmacology & Therapeutics, vol. 119, no. 3, 2008, pp. 223-41.
    Westerveld HE, Hoogendoorn M, de Jong AW, et al. Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights. Pharmacol Ther. 2008;119(3):223-41.
    Westerveld, H. E., Hoogendoorn, M., de Jong, A. W., Goverde, A. J., Fauser, B. C., & Dallinga-Thie, G. M. (2008). Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights. Pharmacology & Therapeutics, 119(3), pp. 223-41. doi:10.1016/j.pharmthera.2008.04.009.
    Westerveld HE, et al. Cardiometabolic Abnormalities in the Polycystic Ovary Syndrome: Pharmacotherapeutic Insights. Pharmacol Ther. 2008;119(3):223-41. PubMed PMID: 18602948.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights. AU - Westerveld,H E, AU - Hoogendoorn,M, AU - de Jong,A W F, AU - Goverde,A J, AU - Fauser,B C J M, AU - Dallinga-Thie,G M, Y1 - 2008/06/17/ PY - 2008/04/14/received PY - 2008/04/28/accepted PY - 2008/7/8/pubmed PY - 2009/2/24/medline PY - 2008/7/8/entrez SP - 223 EP - 41 JF - Pharmacology & therapeutics JO - Pharmacol. Ther. VL - 119 IS - 3 N2 - The polycystic ovary syndrome (PCOS) affects 5-10% of all premenopausal women. It is diagnosed by a combination of oligo-amenorrhea and hyperandrogenism (NIH criteria) or by the presence of two out of three of: oligo-amenorrhea, hyperandrogenism, polycystic ovaries on ultrasound (Rotterdam criteria). PCOS is associated with obesity, insulin resistance and dyslipidemia. Different patterns of dyslipidemia can be present, both in lean and obese PCOS. Low HDL-cholesterol, with or without elevated TG, is the most prominent lipid abnormality. In addition, smaller HDL and LDL particles and elevated postprandial TG responses are reported. Hyperandrogenism, anovulation and insulin resistance affect multiple steps in lipid metabolism in PCOS, as will be discussed. Surrogate markers for atherosclerosis are consistently abnormal in PCOS, while studies on clinical CVD endpoints are limited and non-conclusive. The (pharmaco-) therapy of dyslipidemia in PCOS will be discussed. In addition, the effects of other PCOS related (pharmaco-) therapies, primarily aimed at hyperandrogenism, anovulation or insulin resistance, on lipid metabolism will be addressed. SN - 0163-7258 UR - https://www.unboundmedicine.com/medline/citation/18602948/Cardiometabolic_abnormalities_in_the_polycystic_ovary_syndrome:_pharmacotherapeutic_insights_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0163-7258(08)00099-5 DB - PRIME DP - Unbound Medicine ER -